Holding place for old articles.
As an African-American man entering a Caucasian-dominated industry, Solomon Graham wasn’t intimidated when he founded Quality Biological in 1983, investing $10,000 of his own money to start the business.
The Gaithersburg company is one of the longest-operating biotechs in Montgomery County and has grown into a multimillion-dollar enterprise. It provides products and supplies for molecular and cell biology laboratories to use in infectious disease and cancer research.
Investments in electronic health records, tools to help hospitals absorb physician practices anda group working with hospital systems to help them set up their own insurance plans. Those three health IT companies helped drive venture capital investment in the software sector, which hit a 12-year high in the third quarter. Medical device and biotechnology companies collectively marked their lowest investment for a nine month period since 2005, according to the MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association. It is based on data from Thomson Reuters.
About $3.6 billion was invested in the software sector and there were 42o deals in the quarter.
You can purchase 14 gallons of organic milk or 396 lollipops. You can give her 33 rides on the Ferris wheel at the state fair, or you can get him a couple of violin lessons. You could put the money in a savings account, you could buy her her very own LeapFrog LeapPad Explorer digital learning tablet, or you could buy enough pizzas to feed all of her friends on the block. So many options, so many choices.
I took that money and got my daughter’s genes tested, ordering up an analysis of the composition of her very small self and its odds of living a long and healthy life. And in so doing, I in some small way tied her fate to the success of the company doing the analysis, a genetic-testing startup called 23andMe in Mountain View, California.
The latest of edition of Mtech News published by Maryland Technology Enterprise Institute.
AstraZeneca and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) today announced a collaborative program to support academic research proposals using open innovation as a catalyst for drug discovery. The program will connect expert physicians and scientists with a wide range of high-quality, small molecule compounds and biologics developed by AstraZeneca.
Successful research proposals submitted from academic institutes in Taiwan will be funded by the NRPB to explore new therapeutic uses for specific AstraZeneca compounds which may in turn lead to the development of novel therapies for patients. Further financial details were not disclosed. Areas of high interest include cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Billionaire oilman T. Boone Pickens plans to give Johns Hopkins University $20 million to help spur potentially vision-saving research at the school’s Wilmer Eye Institute.
The gift will be included in the 85-year-old’s estate and will create an endowment to fund a T. Boone Pickens Scholars program supporting scientists.
Each year, a committee of Cleveland Clinic doctors asks hundreds of their colleagues to weigh in on which emerging healthcare technologies they think will help shape their practice over the next 12 months.
Then, the committee evaluates nominations based on clinical impact, probability of commercial success, progress in commercialization and significant human interest, and produces a top 10 list announced at the end of the Clinic’s annual Medical Innovations Summit.
Biocrossroads, which provides money and support to Indiana’s life sciences industry, announced the seven finalists who stand to gain startup funding in its annual New Venture Competition. Six have biotech or healthcare in their sights. On Oct. 21, five of these companies will compete for $25,000 and access to the Indiana Seed II Fund‘s staff and network for early-stage business support at the Indiana Life Sciences Summit. Second and third place in this competition will rake in $15,000 and $10,000 respectively.
“The New Venture Competition has proven to be a great way for us to find and reward promising companies, and is an excellent opportunity for the competingcompanies to gain some exposure within Indiana’s life sciences community,’ David Johnson, president and CEO of BioCrossroads, said in a release.
StartUp Health, a New York-based incubator for health technology startups, admitted 14 new companies into its three-year development program this week. The program, which received 1,200 applications in the past year, aims to give new medical companies long-term mentoring and access to capital.
The new entrants include companies working on medication adherence, remote medical services and patient engagement in physical therapy. Cohero Health, a one-year-old company based in New York, aims to help kids with chronic asthma manage their condition.
Your liver could be “eating” your brain, new research suggests.
People with extra abdominal fat are three times more likely than lean individuals to develop memory loss and dementia later in life, and now scientists say they may know why.
